Improved Sleep across Europe

This set pairs our CJC-1295 & IPAMORELIN pen with our MOTS-C 32 pen. The first is the reason the bundle carries the word sleep: it is a growth-hormone-axis pair, and the largest growth hormone pulse of the day happens shortly after you fall asleep. The second has no sleep literature at all and is here for a different reason.

Why nocturnal growth hormone is the whole argument

Growth hormone is secreted in pulses; in healthy young adults the major episode occurs shortly after sleep onset, in association with the first period of slow-wave sleep; in men roughly 70% of daily GH output occurs during early sleep (Van Cauter E, Plat L, Copinschi G. Interrelations between sleep and the somatotropic axis. Sleep 1998. PMID 9779515). The sleep-onset pulse is driven by a surge of hypothalamic GHRH, and slow-wave sleep and GH output track each other. The association was first described in 1968 (Takahashi Y, Kipnis DM, Daughaday WH. Growth hormone secretion during sleep. J Clin Invest 1968. PMID 5675428).

That is why a GH-axis pen ends up under sleep. The inference you might draw is that deep sleep produces the GH pulse, so a compound that raises GH should improve deep sleep. The established direction is the first half only. Sleep architecture drives the hormone; the reverse — that raising the hormone pharmacologically improves the sleep — is a separate claim, and it is the one the trials below did not test.

Amplify and trigger: the two inputs the pen targets

Growth hormone release has two independent inputs at the pituitary. CJC-1295 is a GHRH analogue: it raises the ceiling of a pulse. Ipamorelin acts on the ghrelin receptor: it provides the trigger for a pulse to occur. Because the inputs are independent, the convention is to pair them: one amplifies the signal, the other fires it. That is why they are sold as a single CJC-1295 & IPAMORELIN pen rather than two (what is CJC-1295 & Ipamorelin).

The human evidence for the two halves is uneven. Teichman and colleagues ran two randomised, placebo-controlled, double-blind trials of CJC-1295 in healthy adults aged 21 to 61 and reported that a single subcutaneous injection raised mean plasma GH two- to ten-fold for six days or more and IGF-1 1.5- to three-fold for nine to eleven days, with an estimated half-life of 5.8 to 8.1 days (Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab 2006. PMID 16352683). Ionescu and Frohman then asked whether the natural pulsatile pattern survives continuous stimulation, and reported that it does (Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab 2006. PMID 17018654). That matters here: a compound that flattened the nocturnal pulse would be working against the physiology the sleep rationale rests on.

Ipamorelin’s characterisation is preclinical. Raun and colleagues identified it as the first selective GH secretagogue, releasing GH with less effect on other pituitary hormones than earlier secretagogues (Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822). No human dose-ranging trial has been published for it.

What was measured, and what was not

Measured in published human trials	Not measured in any published trial
Plasma GH and IGF-1 after CJC-1295	Sleep latency
Persistence of GH pulsatility on CJC-1295	Slow-wave sleep duration
Half-life and tolerability of CJC-1295	Subjective sleep quality or polysomnography

No published human trial of CJC-1295 or ipamorelin has recorded a sleep endpoint; the human work measured hormone concentrations and nothing else. A mechanistic rationale for sleep exists; sleep-endpoint evidence does not.

Where MOTS-c fits, and where it does not

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial rather than nuclear DNA, described in mice as activating AMPK through the folate–AICAR route and preventing diet-induced obesity and insulin resistance (Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015. PMID 25738459). Its evidence is entirely preclinical (cell culture and rodent models, with no published human trial), and nothing in that literature concerns sleep. It is in this set because of where it sits in our catalogue, under energy and recovery, next to a pen also filed under recovery. No study connects it to sleep. The MOTS-C 32 pen and what is MOTS-c say the same.

Where the evidence for the pair stops

No published trial has administered MOTS-c together with CJC-1295 and ipamorelin, in humans or in animals. The GH pair itself has never been tested together in a published human trial either; the CJC-1295 figures above are for CJC-1295 alone. There is no long-term human safety data for any of the three, and none holds a marketing authorisation, so no post-marketing surveillance collects adverse-event reports. What has been reported is set out at reported adverse events. CJC-1295 and ipamorelin are prohibited at all times under WADA. We do not tell you how to combine or sequence the pens.

Who typically chooses this set

You are usually browsing the sleep or recovery goal and want the GH-axis pen together with the mitochondrial peptide, knowing the sleep connection is a rationale rather than a measured result. If you would rather pair the GH pen with NAD+, Prime Performance does that. Both pens are batch-tested by an independent laboratory for identity, purity and sterility; your lot’s certificate is reachable from the QR code on the pen or from the certificate index.